Expression of Claudin-1 and -7 in Clear Cell Renal Cell Carcinoma and Its Clinical Significance by Shin, Hong Il et al.
Korean Journal of Urology
Ⓒ The Korean Urological Association, 2011 317 Korean J Urol 2011;52:317-322
www.kjurology.org
DOI:10.4111/kju.2011.52.5.317
Urological Oncology
Expression of Claudin-1 and -7 in Clear Cell Renal Cell Carcinoma 
and Its Clinical Significance
Hong Il Shin, Byung Hoon Kim, Hyuk Soo Chang, Chun Il Kim, Hye Ra Jung
1, Choal Hee Park
Departments of Urology and 
1Pathology, Keimyung University School of Medicine, Daegu, Korea
Purpose: We investigated the correlations between the expression of claudin-1 and 
claudin-7 in clear cell renal cell carcinoma (clear cell RCC) and clinical parameters.
Materials and Methods: The subjects of this study were 119 patients with confirmed 
clear cell RCC between January 2000 and December 2007. Their RCC tissues were im-
munohistochemically stained for claudin-1 and claudin-7. The correlations between 
the expression of claudin and parameters such as sex, age, body mass index (BMI), tu-
mor size, TNM stage, Furhman nuclear grade, postoperative distant metastasis, and 
cancer-specific survival were analyzed.
Results: Among the total 119 subjects, claudin-1 was expressed in 18 (15.1%) and clau-
din-7 in 31 (26.1%). Claudin-1 was expressed in patients who were older (p=0.007), who 
had a greater tumor size (p=0.001), who had a higher pathologic T stage (p=0.009), who 
had preoperative distant metastasis (p=0.035), and who had a higher Furhman nuclear 
grade (p=0.004). Claudin-7 was expressed only in patients who had a higher Furhman 
nuclear grade (p=0.031). The risk of postoperative distant metastasis was associated 
with the expression of claudin-1 (p＜0.001) but not with the expression of claudin-7 
(p=0.668). The expression of claudin-1 and -7 was not associated with cancer-specific 
survival (p＞0.05).
Conclusions: In clear cell RCC, claudin-1 was expressed in patients who were older and 
who had a greater tumor size, who had higher T or M stages, and who had a higher 
Furhman nuclear grade. The expression of claudin-1 was associated with a higher risk 
of postoperative distant metastasis. 
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INTRODUCTION
Many factors are involved in the development, advance-
ment, and metastasis of malignant tumors. Recently, there 
has been increasing attention paid to the interaction be-
tween cancer cells and the adjacent normal cells. Cell bind-
ing among normal cells connects the cells to each other and 
induces a stable interrelation, and zonula adherens, des-
mosomes, zonula occludens, and the tight junction are in-
volved [1]. The tight junction consists of three integral 
transmembrane proteins: occludins, claudins, and junc-
tional adhesion molecules [1-3]. Claudin, one of the main 
proteins that form epithelial tight junctions, was first dis-
covered in 1998, and 24 types have been reported to date 
[4]. The up-regulation or down-regulation of claudin is 
known to be related to the carcinogenesis and metastasis 
of various cancers, such as stomach cancer, colon cancer, 
and pancreatic cancer [5-7]. However, studies of the clinical 
correlation between various cancers and the expression of 
claudin have shown different results. Thus, studies are ac-
tively being conducted to confirm a clear correlation.
　In this study, we verified the immunohistochemical ex-
pression level of claudin-1 and claudin-7 with clear cell 
RCC and compared the clinicopathologic prognostic factors 
(sex, age, BMI, tumor size, TNM stage, Fuhrman nuclear 
grade, postoperative distant metastasis, and cancer-spe-Korean J Urol 2011;52:317-322
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FIG. 1. Claudin-1 expression in clear cell RCC tissue (anti-claudin-1 antibody, x400). (A) Low expression of membranous claudin-1 protein
in a case of clear cell RCC. (B) High expression of membranous claudin-1 protein in a case of clear cell RCC. Clear cell RCC: clear cell
renal cell carcinoma.
FIG. 2. Claudin-7 expression in clear cell RCC tissue (anti-claudin-7 antibody, x400). (A) Low expression of membranous claudin-7 protein
in a case of clear cell RCC. (B) High expression of membranous claudin-7 protein in a case of clear cell RCC. Clear cell RCC: clear cell
renal cell carcinoma.
cific survival) to investigate the significance of claudin-1 
and claudin-7 expression. 
MATERIALS AND METHODS
1. Subjects
The subjects of this study were the 119 patients whose diag-
nosis of clear cell RCC was confirmed among the 154 patients 
who underwent radical nephrectomy or partial nephrectomy 
for RCC in our hospital from January 2000 to December 
2007. After performing immunohistochemical staining of 
the clear cell RCC tissue for claudin-1 and claudin-7, we in-
vestigated whether the claudin was expressed individually 
and analyzed its correlation with sex, age, BMI, tumor size 
(＜4 cm, 4-7 cm, ＞7 cm), TNM stage, Fuhrman nuclear 
grade, postoperative distant metastasis, and cancer-spe-
cific survival.
2. Immunohistochemical staining
A pathologist researched the H&E staining samples of the 
subjects, marked the representative tumor region, and took 
a core with a 3 mm diameter from the corresponding paraf-
fin block to prepare the tissue microarray (TMA). The TMA 
paraffin block was sectioned into slices of 4 μm thickness 
and they were attached to a slide. Then, they were soaked 
in xylene for 5 minutes three times for paraffin removal and 
washed with distilled water after a moisturizing process. 
The citrate buffer solution (pH 6.0) was used for the pre-Korean J Urol 2011;52:317-322
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TABLE 1. Clinicopathological characteristics of the patients
Variables
Age (mean±SD, yr) 55.7±10.7
BMI (mean±SD, kg/m
2) 24.6±2.7
Tumor size (mean±SD, cm)  5.6±2.8
No. of patients (%)
Sex
　Male
　Female
85 (71)
34 (29)
Pathologic T stage
　T1
　T2
　T3
　T4
71 (59.7)
22 (18.5)
25 (21.0)
1 (0.8)
Clinical N stage
　N0
　N+
114 (95.8)
5 (4.2)
M stage
　M0
　M1
112 (94.1)
7 (5.9)
Fuhrman nuclear grade
　Grade 1
　Grade 2
　Grade 3
　Grade 4
2 (1.7)
66 (55.5)
37 (31.1)
14 (11.8)
Postoperative distant metastasis
a
　Yes
　No
18 (19.1)
94 (80.9)
BMI: body mass index, 
a: excluding preoperative distant meta-
stasis
treatment to recover the antigenicity. The staining was 
performed by using UltraVision LP detection (Thermo 
Scientific, Freemont, CA, USA) and Autostainer360 (Lab 
Vision, Fremont, CA, USA). The primary antibody was di-
luted with Claudin-1 (ab15098, Abcam, Cambridge, UK) 
and Claudin-7 (ab27487, Abcam, Cambridge, UK) at ratios 
of 1:200 and 1:500, respectively, and underwent reaction 
for 40 minutes at room temperature. Mayer's hematoxylin 
was used as the contrast staining, and an optical micro-
scope was used for observation.
3. Evaluation of immunohistochemical staining
In determining the positive expression of claudin-1 and 
claudin-7 in this study, the cases in which claudin-1 and 
claudin-7 stained along the cell membrane of a tumor cell 
were read as positive in the region where the tumor cell ra-
tio was over 5% (Fig. 1, 2).
4. Statistical analysis
Fisher’s exact test and linear by linear association were 
used to examine differences in the expression of claudin-1 
and claudin-7 depending on the clinicopathological find-
ings of the clear cell RCC. Kaplan-Meier analysis was used 
for the survival analysis. p-values of less than 0.05 were 
considered statistically significant. We used the statistical 
program SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
1. Clinicopathologic characteristics
Clear cell RCC was found in a total of 119 subjects including 
85 males (71%) and 34 females (29%). The patients’ mean 
age was 55.7±10.7 years. The mean BMI was 24.6±2.7 
kg/m
2, and the mean tumor size was 5.6±2.8 cm. 
　The number of patients with preoperative distant meta-
stasis was 7. The metastasis site was lung, liver, brain, and 
bone. No cases received neoadjuvant therapy, and target 
therapy was done in all cases after radical nephrectomy. 
The mean postoperative distant metastasis period was 
21.7 months in the patients without preoperative distant 
metastasis, and 14 patients died from cancer-related events. 
　The clinicopathologic characteristics such as tumor stage, 
lymph node metastasis, Fuhrman nuclear grade, pre-
operative distant metastasis, and postoperative distant 
metastasis are shown in Table 1. 
2. Correlation between expression of claudin-1 and clin-
icopathologic parameters
Claudin-1 was expressed in 18 cases (15.1%). The claudin-1 
expression increased with age (p=0.007), but no correlation 
was found with sex or BMI (p=0.777 and p=0.559, respec-
tively). The claudin-1 expression was significantly higher 
with larger tumor size (p=0.001), higher pathologic T stage 
(p=0.009), preoperative distant metastasis (p=0.035), and 
higher Fuhrman nuclear grade (p=0.004). Among the pa-
tients without preoperative distant metastasis, the clau-
din-1 expression was higher in the cases in which post-
operative distant metastasis was present (log-rank test, p
＜0.001) (Table 2). However, there was no significant diffe-
rence in the claudin-1 expression according to cancer-spe-
cific survival (p=0.110) (Fig. 3).
3. Correlation between expression of claudin-7 and clin-
icopathologic parameters 
Claudin-7 was expressed in 31 cases (26.1%). The claudin-7 
expression was significantly higher with higher Furhman 
nuclear grade (p=0.031). However, the claudin-7 expression 
was not correlated with age, sex, BMI, tumor size, TNM 
stage, or the existence of postoperative distant metastasis 
(all p＞0.05) (Table 2). There was no significant difference 
between the claudin-7 expression and cancer-specific sur-
vival (p=0.662) (Fig. 3).
DISCUSSION
RCC is the most common primary malignant tumor in 
kidneys. The World Health Organization (WHO) classifies 
the malignant tumors in kidneys into 10 types, among 
which clear cell RCC, papillary RCC, and chromophobe 
RCC are the most common subtypes, accounting for about 
85% to 90% of the total RCC cases [8,9]. 
　Pathologic classification, TNM stage, and clinical opin-
ion of RCC are known as important factors in the patient’s Korean J Urol 2011;52:317-322
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TABLE 2. Associations between claudin-1 and -7 expression and clinicopathologic parameters in clear cell renal cell carcinoma
Claudin-1 expression Claudin-7 expression
Negative (%) Positive (%) p-value Negative (%) Positive (%) p-value
All cases 101 (84.9) 18 (15.1) 88 (73.9) 31 (26.1)
Age (yr)
　＜50 
　50-70 
　＞70
33 (91.7)
61 (87.1)
  7 (53.8)
3 (8.3)
  9 (12.9)
  6 (46.2)
0.007
26 (72.2)
56 (80.0)
  6 (46.2)
10 (27.8)
14 (20.0)
  7 (53.8)
0.309
Sex
　Male
　Female
73 (85.9)
28 (82.4)
12 (14.1)
  6 (17.6)
0.777
62 (72.9)
26 (27.1)
23 (27.1)
  8 (23.5)
0.819
BMI
　＜23
　＞23
25 (89.3)
76 (83.5)
  3 (10.7)
15 (16.5)
0.559  
22 (78.6)
  6 (72.5)
66 (21.4)
25 (27.5)
0.627
Tumor size (cm)
　＜4
　4-7
　＞7
34 (94.4)
47 (85.5)
20 (71.4)
2 (5.6)
  8 (14.5)
  8 (28.6)
0.001
29 (80.6)
38 (69.1)
21 (75.0)
  7 (19.4)
17 (30.9)
  7 (25.0)
0.794
Pathologic T stage
　T1
　T2
　T3
　T4
65 (91.5)
18 (81.8)
17 (68.0)
 1 (100)
6 (8.5)
  4 (18.2)
  8 (32.0)
0 (0)  
0.009
52 (73.2)
19 (86.4)
16 (64.0)
1 (100)
19 (26.8)
  3 (13.6)
  9 (36.0)
0 (0)
0.717
Clinical N stage
　N0
　N＋
97 (85.1)
  4 (80.0)
17 (14.9)
  1 (20.0)
0.566
84 (73.7)
  4 (80.0)
30 (26.3)
  1 (20.0)
1.000
M stage
　M0
　M1
97 (86.6)
  4 (57.1)
15 (13.4)
  3 (42.9)
0.035
83 (74.1)
  5 (71.4)
29 (25.9)
  2 (28.6)
0.876
Fuhrman nuclear grade 0.004 0.031
　Grade 1
　Grade 2
　Grade 3
　Grade 4
 2 (100)
61 (92.4) 
29 (78.4)
  9 (64.3)
0 (0)
5 (7.6)
  8 (21.6)
  5 (35.7)
  1 (50.0)
55 (83.3)
24 (64.9)
  8 (57.1)
  1 (50.0)
11 (16.7)
13 (35.1)
  6 (42.9)
Postoperative distant metastasis
a ＜0.001 0.668
　Yes
　No
  9 (50.0)
87 (92.6)
  9 (50.0)
7 (7.4)
12 (66.7)
72 (76.6)
  6 (33.3)
22 (23.4)
BMI: body mass index, 
a: excluding preoperative distant metastasis
FIG. 3. Kaplan-Meier univariate survival analysis in patients with clear cell carcinoma according to claudin-1 and -7 expression. (A)
Claudin-1. (B) Claudin-7.Korean J Urol 2011;52:317-322
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prognosis [10]. Additionally, various factors in prognosis 
have been studied recently, such as the expression of clau-
din and its value as a prognostic factor. The loss of inter-
cellular adhesion in tumor cells is known to be an important 
process in the intrusion and metastasis of tumor cells to the 
peripheral matrix [11]. Cell binding induces cells to inter-
connect with each other and have stable interrelations, and 
zonula adherens, desmosomes, zonula occludens, and tight 
junction are involved in this interaction [1]. Tight junc-
tional proteins are located in the apical and basolateral sec-
tions of cells, which play an important part in the main-
tenance of polarity of cells, control of paracellular trans-
portation, and barrier functions. As a result, cell binding 
represses the diffusion of the water and ions surrounding 
the cells as well as the internal macromolecules [12], con-
trols the osmotic force, affects cell movement [1,13], and 
maintains homeostasis and cell polarity [2]. Moreover, cell 
binding is known to be involved in cell growth, differ-
entiation, and control of other cellular functions. 
　Claudin, one of the integral transmembrane proteins 
that constitute tight junctions, is the main protein that 
forms the epithelial tight junction, and 24 types have been 
reported to date [4]. The expression of claudins is known 
to be related to the carcinogenesis of various cancers: the 
low expression of claudin-1 and claudin-5 was associated 
with a Gleason score of 7 or higher and a high prostate-spe-
cific antigen value in prostate cancer [14]. Claudin-1 was 
shown to be under- expressed in the tissues of prostate can-
cer, breast cancer, and thyroid cancer [15-17], and clau-
din-1 expression was lost in hepatocellular carcinoma [18]. 
　Although claudin expression varies depending on the tu-
mor, RCC has not been studied much, and only a few ar-
ticles are available about its clinical prognosis in particular. 
Osunkoya et al and Hornsby et al reported that claudin-7 
expression was enhanced in chromophobe RCC [19,20], 
and Fritzsche et al reported that claudin-1 expression was 
found in a small number of clear cell RCC patients but that 
cancer-specific survival was reduced in those patients [21]. 
In our study, claudin-1 expression was found in 15.1% of 
clear cell RCC cases, and it was higher with higher age, 
larger tumor size, higher T stage, preoperative distant 
metastasis, higher Fuhrman grade, and recent postoperative 
distant metastasis. By contrast, claudin-7 expression was 
found in 26.1% of clear cell RCC, and it was higher only with 
higher Fuhrman grade. 
　Because claudin exists at the tight junction between the 
cells and it maintains cellular polarity, serving as a wall, 
a reduction in claudin expression is anticipated as a tumor 
develops. However, according to various clinical results, 
claudin expression varies depending on the subtypes and 
the kinds of cancer [14-21]. Regarding the cause of such a 
contradiction among results, the protein level might have 
been increased as a response to the lost cellular cohesion 
during the malignant degeneration process or by the am-
plification due to mutation of the claudin gene [22]. Also, 
in our study, high stage and Fuhrman grade as well as dis-
tant metastasis were found in the cases in which the clau-
din expression was increased. The accurate role played by 
claudin in malignant cells should be investigated in future 
studies.
　In the present study, we found that the correlation be-
tween the expression of claudin-1 and claudin-7 and can-
cer-specific survival was insignificant (p=0.110 and p= 
0.662, respectively). However, because there is a report that 
cancer-specific survival was reduced in patients in whom 
claudin-1 was expressed [21], and only a limited number 
of studies have been conducted on the relationship between 
claudin and cancer-specific survival until now, more stud-
ies should be carried out in the future to assess the correla-
tion between claudin and cancer-specific survival.
　A limitation of this study is that we had a small number 
of cases of other subtypes except clear cell RCC, such as pap-
illary RCC and chromophobe RCC, and thus the expression 
and clinical characteristics of claudin-1 and claudin-7 were 
not investigated with respect to the other subtypes. Com-
parison of the claudin-1 and claudin-7 expression among 
different RCC subtypes needs to be carried out in the future 
with a larger number of cases.
CONCLUSIONS
In clear cell RCC, the claudin-1 expression was higher with 
higher age, larger tumor size, higher T stage, preoperative 
distant metastasis, and higher Fuhrman nuclear grade. 
When the claudin-1 expression was positive, the risk of 
postoperative distant metastasis was increased. The ex-
pression of claudin-7 was higher in relation to only a higher 
Fuhrman nuclear grade. Claudin-1 and claudin-7 were not 
correlated with cancer-specific survival. In clear cell RCC, 
the claudin-1 expression may be valuable as a clinically 
meaningful prognostic factor of postoperative distant 
metastasis.
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